At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques.

By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process.

We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable.

Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.

TRACER

Aarhusweg 2-1 likely serves as a hub for research, human resources, and business development in the scientific sector.

Aarhusweg 2-1

Ari Aminetzah

This department focuses on identifying growth opportunities and enhancing operational efficiency to drive business success.

Business Development

This department manages and oversees the planning, execution, and management of clinical projects and trials.

Clinical Operations

This department conducts innovative research and applies scientific methods to advance the organization's knowledge and capabilities.

TRACER

Org chart

Teams

Business Development

Clinical Operations

Research and Development

Offices

TRACER

Org chart

Teams

Business Development

Clinical Operations

Research and Development

Offices

Related companies